Skip to Content

Clozapine Side Effects

Not all side effects for clozapine may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to clozapine: oral suspension, oral tablet, oral tablet disintegrating

In addition to its needed effects, some unwanted effects may be caused by clozapine. In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking clozapine:

More common
  • Blurred vision
  • confusion
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fainting
  • fast, pounding, or irregular heartbeat or pulse
  • fever
  • shakiness in the legs, arms, hands, or feet
  • sleepiness or unusual drowsiness
  • sweating
  • trembling or shaking of the hands or feet
  • unusual tiredness or weakness
Less common
  • Anxiety
  • black, tarry stools
  • chest pain
  • chills
  • convulsions
  • cough or hoarseness
  • decrease in the frequency of urination
  • decrease in urine volume
  • difficult or labored breathing
  • difficulty in passing urine (dribbling)
  • discouragement
  • dry mouth
  • feeling sad or empty
  • fever with or without chills
  • frequent strong or increased urge to urinate
  • general feeling of tiredness or weakness
  • headache
  • hyperventilation
  • irritability
  • lack of appetite
  • loss of bladder control
  • loss of interest or pleasure
  • lower back or side pain
  • muscle spasm or jerking of all extremities
  • painful or difficult urination
  • pounding in the ears
  • restlessness or need to keep moving
  • severe or continuing headache
  • shakiness and unsteady walk
  • slurred speech
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • sudden jerky movements of the body
  • sudden loss of consciousness
  • swollen glands
  • throat discomfort
  • tightness in the chest
  • trouble concentrating
  • trouble sleeping
  • unsteadiness, trembling, or other problems with muscle control or coordination
  • Absence of or decrease in movement
  • change in appetite
  • dark urine
  • decreased sexual ability
  • difficult or fast breathing or sudden shortness of breath
  • increased sweating
  • increased thirst
  • increased urination
  • lip smacking or puckering
  • muscle stiffness (severe)
  • nausea
  • puffing of the cheeks
  • rapid or worm-like movements of the tongue
  • swelling or pain in the leg
  • uncontrolled chewing movements
  • uncontrolled movements of the arms and legs
  • unusual bleeding or bruising
  • unusually pale skin
  • vomiting
  • weakness
  • yellow eyes or skin
Incidence not known
  • Abdominal or stomach pain
  • bloating
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • clay-colored stools
  • confusion as to time, place, or person
  • constipation
  • diarrhea
  • epileptic seizure that will not stop
  • feeling that others are watching you or controlling your behavior
  • feeling that others can hear your thoughts
  • feeling, seeing, or hearing things that are not there
  • holding false beliefs that cannot be changed by fact
  • inability to move the eyes
  • increased blinking or spasms of the eyelid
  • indigestion
  • itching
  • joint pain
  • light-colored stools
  • muscle twitching
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • rhythmic movement of the muscles
  • severe mood or mental changes
  • skin rash
  • sticking out of the tongue
  • swelling around the eyes
  • swelling of the body or feet and ankles
  • trouble with speaking
  • unpleasant breath odor
  • unusual behavior
  • unusual excitement, nervousness, or restlessness
  • unusual facial expressions
  • unusual weight gain
  • upper right abdominal or stomach pain
  • vomiting of blood

Some of the side effects that can occur with clozapine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Acid or sour stomach
  • belching
  • feeling of constant movement of self or surroundings
  • heartburn
  • relaxed and calm sensation of spinning
  • sleepiness
Less common
  • Blurred or loss of vision
  • change or problem with discharge of semen
  • disturbed color perception
  • double vision
  • halos around lights
  • inability to sit still
  • increase in body movements
  • muscle pain or ache
  • muscle weakness
  • night blindness
  • nightmares
  • overbright appearance of lights
  • pain in the back, neck, or legs
  • pain in the chest below the breastbone
  • severe muscle stiffness
  • sore tongue
  • stuffy nose
  • tunnel vision
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
Incidence not known
  • Blistering, peeling, or loosening of the skin
  • hives
  • increased sensitivity of the skin to sunlight
  • painful or prolonged erection of the penis
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • reddening of the skin, especially around the ears
  • severe stomach pain
  • severe sunburn
  • sores, welting, or blisters
  • swelling of the eyes, face, or inside of the nose
  • swelling of the salivary glands

For Healthcare Professionals

Applies to clozapine: oral suspension, oral tablet, oral tablet disintegrating


Hematologic side effects have included agranulocytosis, leukopenia, neutropenia, and eosinophilia. Anemia and leukocytosis have been reported in less than 1% of patients. Elevated hemoglobin/hematocrit, increased erythrocyte sedimentation rate (ESR), thrombocytosis, and thrombocytopenia have also been reported; however, causality has not been established. Lymphopenia has also been reported.[Ref]

During premarketing testing, the cumulative incidence of agranulocytosis at one year was approximately 1.3%. A later study has suggested that the cumulative incidence at one year is 0.8%. The incidence of agranulocytosis increases with age and may be higher in women.

The mechanism of clozapine-induced agranulocytosis is not completely understood.

Some investigators have suggested that the presence of HLA-B38 may predispose certain patients to the development of agranulocytosis during clozapine therapy. An increased incidence of clozapine-induced agranulocytosis has been reported in patients of Ashkenazi Jewish ancestry, a population in which HLA-B38 is prevalent.

Another study has suggested that one of the principal metabolites of clozapine, N-desmethylclozapine, is particularly toxic to the bone marrow.

Individuals with a fall in total WBC count to below 2000/mm3 or ANC below 1000/mm3 may not be rechallenged. However, individuals with an initial episode of moderate leukopenia (WBC of at least 2000/mm3 and less than 3000/mm3) have up to a 12 fold increased risk of having a subsequent episode of agranulocytosis upon rechallenge compared to the full cohort of patients treated with clozapine. To reduce the chances of rechallenge occurring in this patient population a report should be filed with the Clozapine National Registry (CNR), phone 1-800-448-5938), a single, national, confidential data base.

Because of the potential of agranulocytosis, clozapine is only available in the United States through distribution systems which ensure that a patient's WBC count and ANC are checked per a predetermined schedule.

Some investigators have suggested that filgrastim, a granulocyte colony stimulating factor, may be useful in the management of clozapine-induced agranulocytosis.

The incidence of agranulocytosis is reported to rise steeply during the first 2 months of therapy, peak at approximately the third month of therapy, and then decrease to approximately 3 per 1000 person-years at 6 months of therapy. After 6 months of therapy the incidence decreases further; however, it never reaches zero.

A 45 year old African American woman with diagnosis of schizophrenia and mild mental retardation developed agranulocytosis after 6 years of continuous clozapine therapy at a dose of 500 mg per day. At the time of this incident, concomitant therapy for the preceding 4 years consisted of olanzapine, benazepril, and haloperidol decanoate injection. Clozapine was discontinued and the WBC count returned to normal limits two days later. The remaining pharmacological therapy remained constant. Clozapine therapy, without granulocyte colony-stimulating factor, was reinitiated two and a half months later under strict monitoring parameters. The dose was gradually titrated over a 5 month period to 800 mg per day. At the time of report, the patient had received clozapine for 3 years following reinitiation without an abnormal blood event.

Several cases of chronic leukocytosis associated with clozapine use have been reported and all appear to be benign. To date, all reported cases of chronic or persistent leukocytosis have occurred in males. In one case series, chronic leukocytosis was tracked for a period of 2 to 5 years in seven patients receiving clozapine (mean dose 457 mg/day; range 50 to 600 mg daily). Leukocytosis resolved in 2 patients when clozapine was discontinued and returned in 1 when the drug was restarted.[Ref]

Nervous system

Symptoms of dystonia may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups. Clozapine, an atypical antipsychotic, is associated with a low incidence of dystonia.

Clozapine may lower the seizure threshold in a dose-dependent fashion.

Rapid dose increase or preexisting epilepsy may increase the incidence of seizures.

Reports of sedation and/or drowsiness appear to decrease with dose reduction or length of clozapine therapy.

Fever, altered consciousness, autonomic dysfunction and muscle rigidity are the hallmarks of the neuroleptic malignant syndrome. The neuroleptic malignant syndrome is associated with a case fatality rate of about 20%. Immediate discontinuation of neuroleptic therapy, consideration of dantrolene therapy, as well as intensive monitoring and supportive care are indicated.

Although considered rare, there have been at least 21 cases of clozapine associated neuroleptic malignant syndrome (NMS) reported. The mean age of patients who developed NMS has been 40 years, the mean dose of clozapine has been 318 mg daily and the mean number of days to onset of NMS has been 218 days. In approximately half the cases, NMS occurred during a dose increase while the remainder of patients were on stable doses.

In one case report involving a 16 year old patient, NMS characterized by fever, autonomic changes, muscle rigidity, and elevated creatine kinase developed at a low dose (12.5 mg) within 8 hours of initiation of treatment.

There are reports of possible clozapine associated atypical neuroleptic malignant syndrome characterized by fever, diaphoresis, no muscle rigidity, and mild or no elevation of creatine kinase level.[Ref]

Nervous system side effects have included drowsiness/sedation (39%), dizziness/vertigo (19%), headache (7%), tremor (6%), syncope (6%), disturbed sleep/nightmares (4%), restlessness (4%), hypokinesia/akinesia (4%), agitation (4%), seizures (3%), rigidity (3%), akathisia (3%), confusion (3%), fatigue (2%), insomnia (2%), hyperkinesia (1%), weakness (1%), lethargy (1%), ataxia (1%), slurred speech (1%), depression (1%), epileptiform movements/myoclonic jerks (1%), and anxiety (1%). Loss of speech, amentia, tics, poor coordination, involuntary movement, stuttering, dysarthria, amnesia/memory loss, histrionic movements, changes in libido, shakiness, Parkinsonism, and irritability have been reported in less than 1% of patients. Delirium, EEG abnormalities, myoclonus, overdose, paresthesia, mild cataplexy, and status epilepticus have also been reported; however, causality has not been established. Dyskinesia, coma, dystonia, and neuroleptic malignant syndrome have been reported rarely. One case of clozapine-induced restless legs syndrome (RLS) has been reported. Symptoms (e.g., unpleasant sensation in calves, burning sensation over feet) of RLS developed on the third day of treatment, recurred on rechallenge, and completely resolved following discontinuation. At least one case of reversible Pisa syndrome has also been reported. In addition, clozapine-induced oculogyric crises have also been reported. Postmarketing clinical experience has included obsessive compulsive symptoms.[Ref]


Specific subtypes of colitis associated with clozapine have included eosinophilic, neutropenic, pseudomembranous, necrotizing, and microscopic colitis.

Elderly patients may be more susceptible to the anticholinergic effects of clozapine, such as constipation.

Hypersalivation may be dose-dependent.

One hypothesis is that hypersalivation may be due to the blockade of alpha-2 adrenoceptors.

Some case reports have suggested that clozapine may rarely cause pancreatitis.

There have been rare reports of severe diarrhea in association with lymphopenia and/or neutropenia.[Ref]

Gastrointestinal side effects have included hypersalivation (31% to 80%), salivation (31%), constipation (14%), dry mouth (6%), nausea (5%), abdominal discomfort/heartburn (4%), vomiting (3%), and diarrhea (2%). Abdominal distention, gastroenteritis, rectal bleeding, nervous stomach, abnormal stools, hematemesis, gastric ulcer, bitter taste, eructation, polydipsia, and dry throat have been reported in less than 1% of patients. Acute pancreatitis, dysphagia, fecal impaction, intestinal obstruction, paralytic ileus, and swelling of salivary gland have also been reported; however, causality has not been established. There have been a number of case reports in the literature citing clozapine as a potential cause of colitis. Clozapine has also been associated with rare cases of esophageal dysfunction resulting in dysphagia.[Ref]


Cardiovascular side effects have included tachycardia (25%), hypotension (9%), hypertension (4%), chest pain/angina (1%), and ECG/cardiac abnormalities (1%). Edema, palpitations, phlebitis/thrombophlebitis, cyanosis, premature ventricular contraction, bradycardia, and nose bleed have been reported in less than 1% of patients. Atrial or ventricular fibrillation, periorbital edema, venous thromboembolism (i.e., deep vein thrombosis), hypercholesterolemia, and hypertriglyceridemia have also been reported. Polyserositis, pericarditis, pericardial tamponade, pericardial effusion, and potentially fatal myocarditis and cardiomyopathy have been reported rarely. Postmarketing clinical experience has included ventricular tachycardia, cardiac arrest, QT prolongation, and Torsades de Pointes.[Ref]

Elderly patients, particularly those with preexisting cardiovascular dysfunction, may be more susceptible to cardiovascular side effects, especially orthostatic hypotension and tachycardia. In addition, an increased risk of mortality, possibly due to heart failure or sudden death, has been reported with the use of atypical antipsychotic agents in the treatment of behavioral disorders in the elderly patient with dementia.

Collective data gathered from 17 placebo-controlled clinical studies (n=5106) involving the use of atypical antipsychotic agents for the treatment of behavioral disorders in the elderly patient with dementia showed a risk of death 1.6 to 1.7 times greater in the drug treated patient than in the placebo treated patient. The average length of duration for the trials was 10 weeks with the cause of death in the majority of cases, though not all, reported as either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Although clozapine was not included in these studies, the consistent findings across all three relevant chemical classes support the opinion that these findings are likely to be applicable to all atypical antipsychotic agents. Clozapine is not approved by the FDA for use in the treatment of behavioral disorders in elderly patients with dementia.

The results of a large retrospective cohort study appear to indicate that atypical antipsychotic agents (i.e., risperidone, olanzapine, clozapine, quetiapine) increase the risk of venous thromboembolism in elderly patients; however, these events seem to be rare.

Orthostatic hypotension (sometimes associated with syncope and rarely associated with cardiovascular collapse) has been reported particularly at initial titration in association with rapid dose escalation and has been reported with the first dose.

Case reports have suggested that clozapine may cause a paradoxical increase in blood pressure. A chart review (n=82) revealed the incidence of hypertension to be higher in first six months of clozapine therapy.

One recent study has suggested that mild tachycardia may occur in as many as 51% of treated patients and a case report has suggested that the tachycardia may be associated with PVCs.

There are reports of numerous cases of myocarditis (including eighteen deaths) and forty one cases of cardiomyopathy (including 10 deaths). Clozapine associated myocarditis has been reported to occur most often within one to two months of starting clozapine, but it may develop at any time while on clozapine and may even occur at very low doses. Fatal myocarditis is reportedly more likely to occur during (but not limited to) the first month of therapy.

One study (n=61) reported that although a substantial portion of patients treated with clozapine developed ECG abnormalities, most of the abnormalities were benign and did not hinder further treatment.[Ref]


Hepatic side effects have included transient moderate asymptomatic elevations in liver function tests in up to 50% of patients. Cholestasis, hepatitis, and jaundice have also been reported; however, causality has not been established. One case of reversible marked hepatotoxicity has been reported.

Postmarketing reports: Hepatotoxicity, hepatic steatosis, hepatic necrosis, hepatic fibrosis, hepatic cirrhosis, liver injury (hepatic, cholestatic, and mixed), and liver failure[Ref]


Psychiatric side effects have included delusions, hallucinations, and paranoia in less than 1% of patients. Obsessive-compulsive symptoms, worsening of bulimia nervosa, and exacerbation of psychosis have also been reported. Rebound psychosis (or supersensitivity psychosis) may occur after withdrawal of clozapine therapy.[Ref]


Hypersensitivity side effects have included photosensitivity, vasculitis, erythema multiforme, and Stevens-Johnson Syndrome. Bronchospasm, respiratory arrest, cardiovascular collapse, polyserosits, and hypersensitivity myocarditis have also been reported.[Ref]


Elderly patients may be more susceptible to the anticholinergic effects of clozapine, such as urinary retention.[Ref]

Genitourinary side effects have included urinary abnormalities (2%), incontinence (1%), abnormal ejaculation (1%), urinary urgency/frequency (1%), and urinary retention (1%). Dysmenorrhea, impotence, breast pain/discomfort, vaginal itch/infection, hot flashes, and hyperuricemia have been reported in less than 1% of patients. Acute interstitial nephritis and priapism have also been reported; however, causality has not been established.

Postmarketing reports: Nocturnal enuresis[Ref]


Endocrine side effects have included hyperglycemia, hyponatremia, clozapine induced or exacerbated diabetes mellitus, and diabetic ketoacidosis.[Ref]

Numerous studies have demonstrated that clozapine treatment is associated with an increased risk for development or exacerbation of diabetes mellitus. Cases of transient hyperglycemia, diabetic ketoacidosis, new onset diabetes, and exacerbation of preexisting diabetes have been reported. In some studies, the prevalence of clozapine related diabetes has ranged from 4% to 36.6%. In one study, the prevalence of diabetes was considerably higher among patients taking clozapine compared with the general population (25.7% vs 7.9%, respectively). Attempts to associate the frequency of clozapine related diabetes with specific risk factors, other than those known for the general population (e.g., family history, obesity, age group), have been unsuccessful and in some cases resulted in conflicting data. Compared to conventional antipsychotics (i.e., haloperidol, chlorpromazine), the risk of diabetes is higher among patients receiving clozapine.

A study of U.S. military veterans with schizophrenia has reported that patients on clozapine had 1.48 times as many cases of diabetes when compared to patients taking decades old drugs for psychosis including haloperidol, thioridazine, and others.

A survey of FDA MedWatch reports of the development or exacerbation of diabetes, or hyperglycemia, in patients receiving clozapine therapy (n=384) concluded a possible causal relationship may exist. The results stated the onset of hyperglycemia may be rapid, within the first 3 months of clozapine therapy, and severe. There was no obvious association between dose and severity of hyperglycemia or time to onset of hyperglycemia in this patient population. In addition, the reports that were complete suggest the risk may not end with extended clozapine therapy, and, in some cases, clozapine-induced sedation may delay the diagnosis of hyperglycemia.

Additional studies have confirmed that patients receiving atypical antipsychotics (i.e., clozapine, risperidone, olanzapine, quetiapine, ziprasidone) are at an increased risk of developing hyperglycemia and/or diabetes mellitus.[Ref]


Musculoskeletal side effects have included muscle weakness, back, neck, and leg pain, muscle spasm, and muscle pain/ache in 1% of patients. Twitching and joint pain have been reported in less than 1% of patients. Myasthenic syndrome and rhabdomyolysis have been reported; however, causality has not been established. One case report has suggested that clozapine may induce dramatic elevations in creatine phosphokinase (CPK) levels (without other features of the neuroleptic malignant syndrome).[Ref]


A 55 year old female with a history of paranoid hallucinatory schizophrenia developed systemic lupus erythematosus (SLE) following 15 years of continuous therapy with clozapine 200 mg per day. Clinical symptoms resolved and the elevated erythrocyte sedimentation rate (ESR) returned to normal within 2 weeks of discontinuation of clozapine. Subsequently, several pharmacological options were tried to treat the patient's schizophrenia; however, following a risk benefit analysis clozapine therapy was restarted. The clinical symptoms and lab findings indicating SLE returned within weeks of therapy reinitiation. The patient consented to continue on clozapine therapy with appropriate monitoring.

Clozapine-induced systemic lupus erythematosus has been reported in a 32 year old patient with schizophrenia and confirmed upon rechallenge. Clinical symptoms and laboratory markers (i.e., antinuclear antibodies (ANA), erythrocyte sedimentation rate (ESR)) completely resolved following discontinuation of clozapine after both the first exposure and the rechallenge.[Ref]

Immunologic side effects have included asymptomatic antiphospholipid antibodies (1 small study), acute reaction resembling systemic lupus erythematosus (1 case report), and systemic lupus erythematosus.[Ref]


Ocular side effects have included visual disturbances (5%). Mydriasis, eyelid disorder, bloodshot eyes, and nystagmus have been reported in less than 1% of patients. Narrow angle glaucoma has also been reported; however, causality has not been established. Oculogyric crisis has been reported rarely. Pigmentary changes affecting the cornea and retina have been reported.[Ref]


Other side effects have included anorexia (1%), sweating (6%), fever (5%), and tongue numb/sore (1%). Chills (with and without a fever), malaise, appetite increase, ear disorder, hypothermia, and numbness have been reported in less than 1% of patients. Sepsis has been reported; however, causality has not been established. Transient hyperthermia has been reported in as many as 50% of patients started on clozapine therapy.[Ref]

Hyperthermia most commonly occurs between days 8 and 16 of treatment and may last several days.

Clozapine related fever is generally benign but difficult to assess and manage as it can be confused with much more serious conditions.[Ref]


Dermatologic side effects have included rash (2%). Pruritus, pallor, eczema, erythema, bruise, dermatitis, petechiae, and urticaria have been reported in less than 1% of patients. Photosensitivity, vasculitis, erythema multiforme and Stevens-Johnson Syndrome have been reported; however, causality has not been established.[Ref]


Respiratory side effects have included throat discomfort, dyspnea, and nasal congestion in 1% of patients. Coughing, pneumonia, pneumonia like symptoms, rhinorrhea, hyperventilation, wheezing, bronchitis, laryngitis, and sneezing have been reported in less than 1% of patients. Aspiration, pleural effusion, and pulmonary embolism have also been reported; however, causality has not been established. Pleural inflammation/effusions have been reported rarely. Postmarketing clinical experience has included pneumonia and lower respiratory tract infection some of which were fatal.[Ref]

An increased risk of mortality, possibly due to an infection, such as pneumonia, has been reported with the use of atypical antipsychotic agents in the treatment of behavioral disorders in the elderly patient with dementia.

Collective data gathered from 17 placebo-controlled clinical studies (n=5106) involving the use of atypical antipsychotic agents for the treatment of behavioral disorders in the elderly patient with dementia showed a risk of death 1.6 to 1.7 times greater in the drug treated patient than in the placebo treated patient. The average length of duration for the trials was 10 weeks with the cause of death in the majority of cases, though not all, reported as either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Although clozapine was not included in these studies, the consistent findings across all three relevant chemical classes support the opinion that these findings are likely to be applicable to all atypical antipsychotic agents. Clozapine is not approved by the FDA for use in the treatment of behavioral disorders in elderly patients with dementia.[Ref]


One study has reported an average weight gain of 8.9% of body weight during the first 16 weeks of clozapine therapy.[Ref]

Metabolic side effects have included weight gain in up to 67% of patients. Binge eating and increases in food craving have been associated with clozapine. Weight loss has also been reported; however, causality has not been established. Hypercholesterolemia and hypertriglyceridemia have been reported very rarely. Studies have shown that patients receiving clozapine are at an increased risk of developing metabolic syndrome (a clustering of risk factors such as dyslipidemia, hypertension, hyperglycemia for cardiovascular disease). Postmarketing clinical experience has included new onset diabetes.[Ref]


A 33 year old male titrated to clozapine 100 mg per day developed acute interstitial nephritis over seven to fourteen days following initiation of clozapine therapy. Concomitant medications included valproic acid, risperidone, and gabapentin. All medications, except valproic acid, were discontinued and the patient improved within one week.

A 49 year old male developed acute interstitial nephritis within 10 days following initiation of clozapine therapy. The patient recovered following discontinuation of clozapine.[Ref]

Renal side effects have rarely included acute interstitial nephritis.

Postmarketing reports: Renal failure[Ref]


1. Raison CL, Guze BH, Kissell RL "Successful treatment of clozapine-induced agranulocytosis with granulocyte colony-stimulating factor." J Clin Psychopharmacol 14 (1994): 285-6

2. Madhusoodanan S, Cuni L, Brenner R, Sajatovic M, Palekar N, Amanbekova D "Chronic leukocytosis associated with clozapine: a case series." J Clin Psychiatry 68 (2007): 484-8

3. Kleinerman MJ "Controversy grows over monitoring system for new schizophrenia drug." JAMA 264 (1990): 2488,

4. Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P "Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic." Acta Psychiatr Scand 56 (1977): 241-8

5. Schulte PF "Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring." Ann Pharmacother 40 (2006): 683-8

6. Marchesi C, Paini M, Tamborini S, Ampollini P, Maggini C "Recurrence of Clozapine-Induced Agranulocytosis." J Clin Psychopharmacol 25 (2005): 276-277

7. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA "Clozapine-induced agranulocytosis. Incidence and risk factors in the United States." N Engl J Med 329 (1993): 162-7

8. Tiihonen J, Paanila J "Eosinophilia associated with clozapine." Lancet 339 (1992): 488

9. Clozapine Study Group "The safety and efficacy of clozapine in severe treatment-resistant schizophrenia patients in the UK." Br J Psychiatry 163 (1993): 150-4

10. "Product Information. Clozaril (clozapine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.

11. Gerson SL, Guillion G, Hong-Shen Y, Masor C "Granulocyte colony-stimulating factor for clozapine-induced agranulocytosis." Lancet 340 (1992): 1097

12. Cates M, Lusk K, Wells BG, Guthrie TC "Nonleukopenic neutropenia in a patient treated with clozapine." N Engl J Med 326 (1992): 840-1

13. Weide R, Koppler H, Heymanns J, Pfluger KH, Havemann K "Successful treatment of clozapine induced agranulocytosis with granulocyte-colony stimulating factor (G-CSF)." Br J Haematol 80 (1992): 557-9

14. Safferman AZ, Lieberman JA, Alvir JMJ, Howard A "Rechallenge in clozapine-induced agranulocytosis." Lancet 339 (1992): 1296-7

15. Gerson SL "Clozapine--deciphering the risks.." N Engl J Med 329 (1993): 204-5

16. Hummer M, Kurz M, Barnas C, Fleischhacker WW "Transient neutropenia induced by clozapine." Psychopharmacol Bull 28 (1992): 287-90

17. Small JG, Weber MC, Klapper MH, Kellams JJ "Rechallenge of late-onset neutropenia with clozapine." J Clin Psychopharmacol 25 (2005): 185-6

18. Gerson SL "G-CSF and the management of clozapine-induced agranulocytosis." J Clin Psychiatry 55 (1994): 139-42

19. Stubner S, Grohmann R, Engel R, et al. "Blood dyscrasias induced by psychotropic drugs." Pharmacopsychiatry 37 Suppl 1 (2004): S70-8

20. Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993): 312-3

21. Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, Lieberman JA "Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis." J Lab Clin Med 119 (1992): 254-66

22. Peck CC "FDA's position on the clozaril patient management system." Hosp Community Psychiatry 41 (1990): 876-7

23. Sedky K, Shaughnessy R, Hughes T, Lippmann S "Clozapine-induced agranulocytosis after 11 years of treatment." Am J Psychiatry 162 (2005): 814

24. Stricklet BHC, Tielens JAE "Eosinophilia with clozapine." Lancet 338 (1991): 1520-1

25. Gerson SL, Arce C, Meltzer HY "N-desmethylclozapine - a clozapine metabolite that suppresses haemopoiesis." Br J Haematol 86 (1994): 555-61

26. Gullion G, Yeh HS "Treatment of clozapine-induced agranulocytosis with recombinant granulocyte colony-stimulating factor." J Clin Psychiatry 55 (1994): 401-5

27. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ "HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia." Arch Gen Psychiatry 47 (1990): 945-8

28. Nielsen H "Recombinant human granulocyte colony-stimulating factor (rhg-csf filgrastim) treatment of clozapine-induced agranulocytosis." J Intern Med 234 (1993): 529-31

29. Esposito D, Rouillon F, Limosin F "Continuing clozapine treatment despite neutropenia." Eur J Clin Pharmacol 60 (2005): 759-764

30. Joseph G, Nguyen V, Smith JD "HLA-B38 and clozapine-induced agranulocytosis." Ann Intern Med 116 (1992): 605

31. Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992): 58-9

32. Cohen BM, Keck PE, Satlin A, Cole JO "Prevalence and severity of akathisia in patients on clozapine." Biol Psychiatry 29 (1991): 1215-9

33. Welch J, Manschreck T, Redmond D "Clozapine-induced seizures and EEG changes." J Neuropsychiatry Clin Neurosci 6 (1994): 250-6

34. Naber D, Leppig M, Grohmann R, Hippius H "Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients." Psychopharmacology (Berl) 99 (1989): s73-6

35. Hung TH, Lee Y, Chang YY, Chong MY, Lin PY "Reversible Pisa Syndrome Induced by Clozapine: A Case Report." Clin Neuropharmacol 30 (2007): 370-372

36. Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993): 1561

37. Dave M "Tardive oculogyric crises with clozapine." J Clin Psychiatry 55 (1994): 264-5

38. Chakraborty R, Chatterjee A "Clozapine-induced oculogyric crises (November)." Ann Pharmacother (2007):

39. Lamberti JS, Bellnier T "Clozapine and tardive dystonia." J Nerv Ment Dis 181 (1993): 137-8

40. Baker RW, Conley RR "Seizures during clozapine therapy." Am J Psychiatry 148 (1991): 1265-6

41. Simpson GM, Cooper TA "Clozapine plasma levels and convulsions." Am J Psychiatry 135 (1978): 99-100

42. Pacia SV, Devinsky O "Clozapine-related seizures: experience with 5,629 patients." Neurology 44 (1994): 2247-9

43. Thomas P, Goudemand M "Seizure with low doses of clozapine." Am J Psychiatry 149 (1992): 138-9

44. Berman I, Zalma A, DuRand CJ, Green AI "Clozapine-induced myoclonic jerks and drop attacks." J Clin Psychiatry 53 (1992): 329-30

45. Skarpathiotakis M, Westreich N "NMS after clozapine initiation." J Am Acad Child Adolesc Psychiatry 44 (2005): 1101-2

46. Devinsky O, Honigfeld G, Patin J "Clozapine-related seizures." Neurology 41 (1991): 369-71

47. Chengappa KNR, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J "The prevalence of akathisia in patients receiving stable doses of clozapine." J Clin Psychiatry 55 (1994): 142-5

48. Haller E, Binder RL "Clozapine and seizures." Am J Psychiatry 147 (1990): 1069-71

49. Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995): 70-3

50. de Leon J, Moral L, Camunas C "Clozapine and jaw dyskinesia: a case report." J Clin Psychiatry 52 (1991): 494-5

51. DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991): 105-7

52. Kastrup O, Gastpar M, Schwarz M "Acute dystonia due to clozapine." J Neurol Neurosurg Psychiatry 57 (1994): 119

53. Duggal HS, Mendhekar DN "Clozapine-Associated Restless Legs Syndrome." J Clin Psychopharmacol 27 (2007): 89-90

54. Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989): s101-4

55. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM "Clozapine in tardive dyskinesia - observations from human and animal model studies." J Clin Psychiatry 55 (1994): 102-6

56. Ackenheil M "Clozapine: pharmacokinetic investigations and biochemical effects in man." Psychopharmacology (Berl) 99 (1989): s32-7

57. Thomas P, Lalaux N, Vaiva G, Goudemand M "Dose-dependent stuttering and dystonia in a patient taking clozapine." Am J Psychiatry 151 (1994): 1096

58. Miller DD "Clozapine and Tardive Dyskinesia." Am J Psychiatry 160 (2003): 588

59. Burke M, Sebastian CS "Treatment of clozapine sedation." Am J Psychiatry 150 (1993): 1900-1

60. Baciewicz AM, Chandra R, Whelan P "Clozapine-associated neuroleptic malignant syndrome." Ann Intern Med 137(5 Part 1) (2002): 374

61. Centorrino F, Price BH, Tuttle M, et al. "EEG abnormalities during treatment with typical and atypical antipsychotics." Am J Psychiatry 159 (2002): 109-15

62. Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991): 99-101

63. Carter J, Thrasher S, Thornicroft G "Cognitive impairment and clozapine." Br J Psychiatry 164 (1994): 132-3

64. Friedman JH "Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases." Mov Disord 9 (1994): 321-4

65. Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991): 102-4

66. Gerlach J, Peacock L "Motor and mental side effects of clozapine." J Clin Psychiatry 55 (1994): 107-9

67. Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ "Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis." J Clin Psychiatry 48 (1987): 263-7

68. Lieberman JA, Safferman AZ "Clinical profile of clozapine: adverse reactions and agranulocytosis." Psychiatr Q 63 (1992): 51-70

69. Meltzer HY, Luchins DJ "Effect of clozapine in severe tardive dyskinesia: a case report." J Clin Psychopharmacol 4 (1984): 286-7

70. Gouzoulis E, Ozdaglar A, Kasper J "Myoclonic seizures followed by grand mal seizures during clozapine treatment." Am J Psychiatry 150 (1993): 1128

71. Devinsky O, Pacia SV "Seizures during clozapine therapy." J Clin Psychiatry 55 (1994): 153-6

72. Dave M "Clozapine-related tardive dyskinesia." Biol Psychiatry 35 (1994): 886-7

73. Chiles JA, Cohn S, McNaughton A "Dropping objects: possible mild cataplexy associated with clozapine." J Nerv Ment Dis 178 (1990): 663-4

74. Elliott ES, Marken PA, Ruehter VL "Clozapine-associated extrapyramidal reaction." Ann Pharmacother 34 (2000): 615-8

75. Patterson BD, Jennings JL "Spiking fever and profuse diarrhea with clozapine treatment." Am J Psychiatry 150 (1993): 1126

76. Mccarthy RH, Terkelsen KG "Esophageal dysfunction in two patients after clozapine treatment." J Clin Psychopharmacol 14 (1994): 281-3

77. Martin A "Acute pancreatitis associated with clozapine use." Am J Psychiatry 149 (1992): 714

78. Pearlman C "Clozapine, nocturnal sialorrhea, and choking." J Clin Psychopharmacol 14 (1994): 283

79. Honigfeld G, Patin J "A two-year clinical and economic follow-up of patients on clozapine." Hosp Community Psychiatry 41 (1990): 882-5

80. Frankenburg FR, Kando J "Eosinophilia, clozapine, and pancreatitis." Lancet 340 (1992): 251

81. Koller EA, Cross JT, Doraiswamy PM, Malozowski SN "Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports." Pharmacotherapy 23 (2003): 1123-30

82. Sim K, Yong TW, Liew E, Choon CH "Clozapine-associated Pseudomembranous Colitis: A Case Report and Review of the Literature." J Clin Psychopharmacol 26 (2006): 89

83. Harvey RJ, Bullock T, Montgomery SA "Diarrhoea during treatment with clozapine: association with lymphocyte count." Br Med J 305 (1992): 810

84. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG "Clozapine and metabolites - concentrations in serum and clinical findings during treatment of chronically psychotic patients." J Clin Psychopharmacol 14 (1994): 119-25

85. Jubert P "Clozapine-related pancreatitis." Ann Intern Med 121 (1994): 722-3

86. Szabadi E "Clozapine-induced hypersalivation and the alpha-2 adrenoceptor." Br J Psychiatry 169 (1996): 380-1

87. Hawe R, Bolton JM "Response to clozapine-induced microscopic colitis: a case report and review of the literature." J Clin Psychopharmacol 28 (2008): 454-5

88. Davdov L, Botts SR "Clozapine-induced hypersalivation." Ann Pharmacother 34 (2000): 662-5

89. Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G "Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents." Arch Intern Med 165 (2005): 2677-82

90. Merrill DB, Dec GW, Goff DC "Adverse Cardiac Effects Associated With Clozapine." J Clin Psychopharmacol 25 (2005): 32-41

91. Henderson DC "Clozapine: diabetes mellitus, weight gain, and lipid abnormalities." J Clin Psychiatry 62 Suppl 23 (2001): 39-44

92. Kerwin R "Adverse reaction reporting and new antipsychotics." Lancet 342 (1993): 1440

93. Casey DE "Dyslipidemia and atypical antipsychotic drugs." J Clin Psychiatry 65 Suppl 18 (2004): 27-35

94. Kang UG, Kwon JS, Ahn YM, Chung SJ, Ha JH, Koo YJ, Kim YS "Electrocardiographic abnormalities in patients treated with clozapine." J Clin Psychiatry 61 (2000): 441-6

95. Testani M "Clozapine-induced orthostatic hypotension treated with fludrocortisone." J Clin Psychiatry 55 (1994): 497-8

96. Lim A, Sivakumaran P, Israel M "Clozapine-associated polyserositis." N Z Med J 116 (2003): U651

97. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC "The effects of novel antipsychotics on glucose and lipid levels." J Clin Psychiatry 63 (2002): 856-65

98. Friedman LJ, Tabb SE, Worthington JJ, Sanchez CJ, Sved M "Clozapine--a novel antipsychotic agent." N Engl J Med 325 (1991): 518-9

99. Pieroni M, Cavallaro R, Chimenti C, Smeraldi E, Frustaci A "Clozapine-induced hypersensitivity myocarditis." Chest 126 (2004): 1703-5

100. Schonfeldt-Lecuona C, Connemann BJ "Sweet's Syndrome and Polyserositis With Clozapine." Am J Psychiatry 159 (2002): 1947

101. Merrill DB, Ahmari SE, Bradford JM, Lieberman JA "Myocarditis during clozapine treatment." Am J Psychiatry 163 (2006): 204-8

102. Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994): 537-44

103. FDA. U.S. Food and Drug Admiinistration. Center for Drug Evaluation and Research "FDA Public Health Advisory. Deaths and antipsychotics in elderly patients with behavioral disturbances. Available from: URL:" ([2005 Apr 11]):

104. Azzam DG, Tay JW, Greeve MA, Harvey JM, Bentel JM "ERK/MAPK regulation of the androgen responsiveness of breast cancer cells." Adv Exp Med Biol 617 (2008): 429-35

105. Bhatti MA, Zander J, Reeve E "Clozapine-induced pericarditis, pericardial tamponade, polyserositis, and rash." J Clin Psychiatry 66 (2005): 1490-1

106. La Grenade L, Graham D, Trontell A "Myocarditis and cardiomyopathy associated with clozapine use in the United States." N Engl J Med 345 (2001): 224-5

107. Rathore S, Masani ND, Callaghan PO "Clozapine-Induced Effuso-Constrictive Pericarditis. Case Report and Review of the Literature." Cardiology 108 (2006): 183-185

108. Hagg S, Spigset O, Bate A, Soderstrom TG "Myocarditis related to clozapine treatment." J Clin Psychopharmacol 21 (2001): 382-8

109. Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D "Clozapine and hypertension: a chart review of 82 patients." J Clin Psychiatry 65 (2004): 686-9

110. Tie H, Walker BD, Singleton CB, et al. "Clozapine and sudden death." J Clin Psychopharmacol 21 (2001): 630-2

111. Kortepeter C, Chen M, Knudsen JF, Dubitsky GM, Ahmad SR, Beitz J "Clozapine and venous thromboembolism." Am J Psychiatry 159 (2002): 876-7

112. Kortner K, Neuhaus AH, Schurer F, Dettling M "Eosinophilia indicating subclinical clozapine-induced pericarditis." J Clin Psychiatry 68 (2007): 1147-8

113. Tanner MA, Culling W "Clozapine associated dilated cardiomyopathy." Postgrad Med J 79 (2003): 412-3

114. Aronowitz JS, Umbricht DSG, Safferman AZ "Clozapine and new-onset ECG abnormalities." Psychosomatics 36 (1995): 82-3

115. Hill GR, Harrison-Woolrych M "Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme." N Z Med J 121 (2008): 68-75

116. Gupta S "Paradoxical hypertension associated with clozapine." Am J Psychiatry 151 (1994): 148

117. Kellner M, Wiedemann K, Krieg JC, Berg PA "Toxic hepatitis by clozapine treatment." Am J Psychiatry 150 (1993): 985-6

118. Mahendran R, Liew E, Subramaniam M "De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study." J Clin Psychiatry 68 (2007): 542-5

119. Patil VJ "Development of transient obsessive-compulsive symptoms during treatment with clozapine." Am J Psychiatry 149 (1992): 272

120. Patel B, Tandon R "Development of obsessive-compulsive symptoms during clozapine treatment." Am J Psychiatry 150 (1993): 836

121. Allen L, Tejera C "Treatment of clozapine-induced obsessive-compulsive symptoms with sertraline." Am J Psychiatry 151 (1994): 1096-7

122. Brewerton TD, Shannon M "Possible clozapine exacerbation of bulimia nervosa ." Am J Psychiatry 149 (1992): 1408-9

123. Varambally S, Howpage P "Acute myocarditis associated with clozapine." Australas Psychiatry 15 (2007): 343-6

124. Stoppe G, Muller P, Fuchs T, Ruther E "Life-threatening allergic reaction to clozapine." Br J Psychiatry 161 (1992): 259-61

125. Annamraju S, Sheitman B, Saik S, Stephenson A "Early Recognition of Clozapine-Induced Myocarditis." J Clin Psychopharmacol 27 (2007): 479-483

126. Daly JM, Goldberg RJ, Braman SS "Polyserositis associated with clozapine treatment." Am J Psychiatry 149 (1992): 1274-5

127. Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994): 619-20

128. Rosen SI, Hanno PM "Clozapine-induced priapism." J Urol 148 (1992): 876-7

129. Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996): 39-40

130. Compton MT, Miller AH "Priapism associated with conventional and atypical antipsychotic medications: A review." J Clin Psychiatry 62 (2001): 362-6

131. Seftel AD, de Tejada IS, Szetela B, Cole J, Goldstein I "Clozapine-associated priapism: a case report." J Urol 147 (1992): 146-8

132. Ziegler J, Behar D "Clozapine-induced priapism." Am J Psychiatry 149 (1992): 272-3

133. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R "Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications." J Clin Psychiatry 59 (1998): 294-9

134. Lamberti JS, Costea GO, Olson D, et al. "Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates." J Clin Psychiatry 66 (2005): 900-6

135. Henderson DC, Cagliero E, Copeland PM, et al. "Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics." J Clin Psychiatry 68 (2007): 533-41

136. Melkersson K, Dahl ML "Adverse metabolic effects associated with atypical antipsychotics : literature review and clinical implications." Drugs 64 (2004): 701-23

137. Gianfrancesco F, Pesa J, Wang RH, Nasrallah H "Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study design." Am J Health Syst Pharm 63 (2006): 431-41

138. Sernyak MJ, Gulanski B, Rosenheck R "Undiagnosed hyperglycemia in patients treated with atypical antipsychotics." J Clin Psychiatry 66 (2005): 1463-7

139. Koller E, Malozowski S, Doraiswamy PM "Atypical antipsychotic drugs and hyperglycemia in adolescents." JAMA 286 (2001): 2547-8

140. Ogilvie AD, Croy MF "Clozapine and hyponatraemia." Lancet 340 (1992): 672

141. Lindenmayer JP, Nathan AM, Smith RC "Hyperglycemia associated with the use of atypical antipsychotics." J Clin Psychiatry 62 Suppl 23 (2001): 30-8

142. Guo JJ, Keck PE, Corey-Lisle PK, et al. "Risk of Diabetes Mellitus Associated With Atypical Antipsychotic Use Among Patients With Bipolar Disorder: A Retrospective, Population-Based, Case-Control Study." J Clin Psychiatry 67 (2006): 1055-1061

143. Citrome LL, Jaffe AB "Relationship of atypical antipsychotics with development of diabetes mellitus." Ann Pharmacother 37 (2003): 1849-57

144. Koller E, Schneider B, Bennett K, Dubitsky G "Clozapine-associated diabetes." Am J Med 111 (2001): 716-723

145. Burton, TM "New antipsychotic-drug class is tied to increase in diabetes. Available from: URL:,,SB106150445385585800,00.html." ([2003 Aug]):

146. Wehring HJ, Kelly DL, Love RC, Conley RR "Deaths From Diabetic Ketoacidosis After Long-Term Clozapine Treatment." Am J Psychiatry 160 (2003): 2241-2242

147. Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7

148. Keshavan MS, Stecker J, Kambhampati RK "Creatine kinase elevations with clozapine." Br J Psychiatry 164 (1994): 118-20

149. Wickert WA, Campbell NRC, Martin L "Acute severe adverse clozapine reaction resembling systemic lupus erythematosus." Postgrad Med J 70 (1994): 940-1

150. Rami AF, Barkan D, Mevorach D, Leitersdorf E, Caraco Y "Clozapine-induced systemic lupus erythematosus." Ann Pharmacother 40 (2006): 983-5

151. Davis S, Kern HB, Asokan R "Antiphospholipid antibodies associated with clozapine treatment." Am J Hematol 46 (1994): 166-7

152. Wolf J, Sartorius A, Alm B, Henn FA "Clozapine-induced lupus erythematosus." J Clin Psychopharmacol 24 (2004): 236-8

153. Borovik AM, Bosch MM, Watson SL "Ocular pigmentation associated with clozapine." Med J Aust 190 (2009): 210-1

154. Kohen I, Afzal N, Hussain S, Manu P "Increases in C-Reactive protein may predict recurrence of clozapine-induced fever." Ann Pharmacother 43 (2009): 143-6

155. Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR "Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine." J Clin Psychiatry 64 (2003): 1133-4

156. Goethe JW, Szarek BL, Caley CF, Woolley SB "Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review." J Clin Psychiatry 68 (2007): 22-8

157. Kluge M, Schuld A, Himmerich H, et al. "Clozapine and Olanzapine Are Associated With Food Craving and Binge Eating: Results From A Randomized Double-Blind Study." J Clin Psychopharmacol 27 (2007): 662-666

158. Lamberti JS, Olson D, Crilly JF, et al. "Prevalence of the metabolic syndrome among patients receiving clozapine." Am J Psychiatry 163 (2006): 1273-6

159. Fraser D, Jibani M "An unexpected and serious complication of treatment with the atypical antipsychotic drug clozapine." Clin Nephrol 54 (2000): 78-80

160. Au AF, Luthra V, Stern R "Clozapine-Induced Acute Interstitial Nephritis." Am J Psychiatry 161 (2004): 1501

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.